Tu J B, Hartridge C, Izawa J
Children's Psychiatric Research Institute (CPRI), London, Ontario, Canada.
J Am Acad Child Adolesc Psychiatry. 1992 Nov;31(6):1137-40. doi: 10.1097/00004583-199211000-00024.
The study of genes, drugs, and behavior in three male adolescents with Prader-Willi syndrome (PWS) revealed a clinical profile that raises questions about the indications for neuroleptic and appetite-suppressing medications in this condition. Evidence of the inadvisability of neuroleptic medication and of the pathophysiology of PWS has led to a remarkable control of violent outbursts and hyperphagia by carbamazepine in one patient afflicted with both PWS and Klinefelter's syndrome. Testosterone and behavioral therapy proved to be useful in the management of two patients. The present observations, which are supported by recent advances in the pathophysiology of satiety, suggest that PWS should be understood as a metabolic disorder and subjected to psychopharmacogenetic study.
对三名患有普拉德-威利综合征（PWS）的男性青少年的基因、药物和行为研究揭示了一种临床特征，这引发了关于在这种情况下使用抗精神病药物和食欲抑制药物的适应症的问题。抗精神病药物不可取的证据以及PWS的病理生理学已导致卡马西平对一名同时患有PWS和克兰费尔特综合征的患者的暴力发作和食欲亢进有显著控制。睾酮和行为疗法被证明对两名患者的治疗有用。目前的观察结果得到了饱腹感病理生理学最新进展的支持，表明PWS应被理解为一种代谢紊乱，并应进行精神心理药物遗传学研究。
